Long-term systemic corticosteroids cause Cushingoid (iatrogenic Cushing) features: moon face, buffalo hump, central truncal obesity with thin extremities, purple abdominal striae, easy bruising and skin thinning, hirsutism, acne, edema, and proximal muscle wasting. Additional long-term harms include osteoporosis with fracture risk, cataracts and glaucoma, peptic ulcer, growth suppression in children, mood and sleep changes, hypertension, hyperglycemia, and adrenal suppression. Management: (1) reassure that the changes are expected pharmacologic effects, not allergy or treatment failure, (2) work with the prescriber on dose minimization, alternate-day dosing when feasible, or steroid-sparing agents, (3) calcium 1000 to 1200 mg and vitamin D 800 to 1000 units daily, weight-bearing exercise, and DEXA bone-density monitoring, (4) low sodium diet to limit fluid retention, (5) fall and fracture precautions, (6) annual eye exam, BP, lipids, and glucose surveillance, (7) skin protection because of fragility. Stopping abruptly or doubling the dose are both contraindicated.
In-depth explanation
The visible Cushingoid syndrome is the most commonly tested adverse-effect cluster of chronic prednisone. The intervention is dose minimization plus bone, eye, mood, and skin surveillance, not stopping or doubling.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.